These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 26109316)

  • 1. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA perspective on companion diagnostics: an evolving paradigm.
    Mansfield EA
    Clin Cancer Res; 2014 Mar; 20(6):1453-7. PubMed ID: 24634468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
    Glorikian H; Warburg RJ; Moore K; Malinowski J
    Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International differences in companion diagnostic approvals: how are we able to manage the differences?
    Shimazawa R; Ikeda M
    Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
    Nobori T; Nomura F
    Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics.
    Goodsaid FM
    Clin Transl Sci; 2019 Sep; 12(5):431-439. PubMed ID: 31162800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
    Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
    Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
    Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
    Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory considerations for companion diagnostic devices.
    Lee EY; Shen HC
    Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
    Fridlyand J; Simon RM; Walrath JC; Roach N; Buller R; Schenkein DP; Flaherty KT; Allen JD; Sigal EV; Scher HI
    Nat Rev Drug Discov; 2013 Oct; 12(10):743-55. PubMed ID: 24008432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
    Sapsford KE; Tezak Z; Kondratovich M; Pacanowski MA; Zineh I; Mansfield E
    Ther Deliv; 2010 Nov; 1(5):631-41. PubMed ID: 22833953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
    Love D; Stratton E; Stocum M
    N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
    Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
    [No Abstract]   [Full Text] [Related]  

  • 20. Approval of novel biomarkers: FDA's perspective and major requests.
    Scherf U; Becker R; Chan M; Hojvat S
    Scand J Clin Lab Invest Suppl; 2010; 242():96-102. PubMed ID: 20515286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.